Maliheh Davari: Exploring CRISPR Activation for Hemophilia at ISTH 2026
Maliheh Davari, Postdoctoral Fellow at Queen’s University, shared a post on LinkedIn:
“I am thrilled to announce that I had the opportunity to present my study, ‘Targeted CRISPRa-Mediated Enhancement of Inverted F8 Exon 1–22 Fragment Expression in Hemophilic Canine Endothelial Cells’, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris.
It was a great privilege to share our work with researchers and clinicians from around the world and to engage in valuable scientific discussions.
I would like to express my sincere gratitude to my supervisor, Dr. David Lillicrap, for his invaluable mentorship, continuous guidance, and unwavering support throughout this project.
Presenting at ISTH has been an enriching experience, and I look forward to continuing this research and contributing to advances in the field of thrombosis and hemostasis.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI